

Axial Spondyloarthritis (Axspa) Market Outlook 2025-2034: Market Share, and Growth Analysis By Types (Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)), By Commercialized Therapies (Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)), By Dosage Form, By Treatment, By End-Use

<https://marketpublishers.com/r/A6100A158DC6EN.html>

Date: October 2025

Pages: 160

Price: US\$ 3,950.00 (Single User License)

ID: A6100A158DC6EN

Abstracts

The Axial Spondyloarthritis (Axspa) Market is valued at USD 8 billion in 2025 and is projected to grow at a CAGR of 9.3% to reach USD 17.8 billion by 2034.

Axial Spondyloarthritis (axSpA) Market Overview

The global axial spondyloarthritis (axSpA) market is experiencing significant growth, primarily driven by rising disease prevalence, enhanced awareness among healthcare providers and patients, and advancements in diagnostic methodologies. Axial spondyloarthritis encompasses a group of chronic inflammatory rheumatic diseases primarily affecting the spine and sacroiliac joints, causing severe pain, stiffness, and reduced mobility. Increasing recognition of the condition, coupled with greater diagnostic accuracy and early intervention strategies, is fueling market growth. substantial developments occurred in the axSpA market, notably the increased adoption of advanced biologic therapies and targeted treatments such as tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors. These innovations significantly improved patient outcomes, reducing disease progression and enhancing quality of life. Additionally, several new therapeutics entered clinical trials, signaling further expansion

and diversification of treatment options. Growing patient advocacy and educational initiatives also contributed to increased diagnosis rates, particularly in developed markets. The axSpA market is projected to sustain robust growth, driven by continued therapeutic innovations, greater adoption of personalized treatment approaches, and expanded patient access to biologic therapies in developing regions. The introduction of novel oral therapies and biosimilars is expected to improve treatment affordability and accessibility. Moreover, increased research into biomarkers for early detection and precision medicine strategies will further shape the market's trajectory, providing significant opportunities for pharmaceutical companies and healthcare providers.

Key Insights Axial Spondyloarthritis (Axspa) Market

Growing adoption of biologic therapies, including TNF and IL inhibitors, for improved disease management and patient outcomes.

Increasing utilization of biosimilars, enhancing treatment affordability and accessibility for axSpA patients globally.

Advancements in personalized medicine, leveraging biomarkers and genetic profiling to tailor therapies effectively.

Enhanced diagnostic accuracy and earlier intervention facilitated by improved imaging techniques and disease awareness campaigns.

Expansion of patient support programs and digital health platforms aimed at improving patient engagement and disease management.

Rising prevalence of axial spondyloarthritis driven by demographic factors, improved diagnosis rates, and increased disease awareness.

Significant advancements in therapeutic treatments, particularly biologics, providing effective disease control and symptom relief.

Strong pipeline of novel drugs and increased investments in clinical research accelerating market expansion.

Increasing healthcare expenditure and improved reimbursement frameworks promoting greater patient access to advanced therapies.

High treatment costs associated with biologics and targeted therapies limiting accessibility, particularly in low- and middle-income regions.

Delayed diagnosis and limited disease awareness among primary care providers, leading to suboptimal disease management in certain regions.

Axial Spondyloarthritis (Axspa) Market Segmentation

By Types

Ankylosing spondylitis (AS)

Non-radiographic axial spondyloarthritis (nr-axSpA)

By Commercialized Therapies

Anti-tumor Necrosis Factor Therapy (TNF)

Anti-Interleukin Therapy (IL)

Anti-Janus Kinase Therapy (JAK)

By Dosage Form

Tablets

Injections

By Treatment

Tumor necrosis factor (TNF) Alpha Inhibitors

Non-steroidal anti-inflammatory drugs (NSAID)

Conventional Disease Modifying Anti-Rheumatic Drugs

Glucocorticoids

Interleukin Blockers

By End-Use

Hospital Pharmacies

Retailer Pharmacies

Online Pharmacy Stores

Key Companies Analysed

Johnson and Johnson Private Limited

Pfizer Inc.

F. Hoffmann-La Roche AG

Merck and Co. Inc.

AbbVie Inc.

Novartis AG

Sanofi S.A

Bristol-Myers Squibb Company

AstraZeneca plc.

Abbott Laboratories

GSK plc.

Eli Lilly and Company

Takeda Pharmaceutical Company Limited

Gilead Sciences Inc.

Teva Pharmaceutical Industries Ltd.

Regeneron Pharmaceuticals Inc.

Biogen Inc.

Vertex Pharmaceuticals Incorporated

UCB S.A.

Boehringer Ingelheim International GmbH.

Horizon Therapeutics Public Ltd Co

Mitsubishi Tanabe Pharma Corporation

Ipsen Technologies Pvt Ltd.

Kyowa Kirin Co. Ltd.

Sun Pharmaceutical Industries Ltd.

Acelyrin Inc.

Nordic Bioscience A/S

Iroko Pharmaceuticals LLC

Celgene Corporation

Pozen Inc.

Axial Spondyloarthritis (Axspa) Market Analytics

The report employs rigorous tools, including Porter's Five Forces, value chain mapping, and scenario-based modeling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Axial Spondyloarthritis (Axspa) Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis' proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Axial Spondyloarthritis (Axspa) market data and outlook to 2034

United States

Canada

Mexico

Europe — Axial Spondyloarthritis (Axspa) market data and outlook to 2034

Germany

United Kingdom

France

Italy

Spain

BeNeLux

Russia

Sweden

Asia-Pacific — Axial Spondyloarthritis (Axspa) market data and outlook to 2034

China

Japan

India

South Korea

Australia

Indonesia

Malaysia

Vietnam

Middle East and Africa — Axial Spondyloarthritis (Axspa) market data and outlook to 2034

Saudi Arabia

South Africa

Iran

UAE

Egypt

South and Central America — Axial Spondyloarthritis (Axspa) market data and outlook to 2034

Brazil

Argentina

Chile

Peru

** We can include data and analysis of additional countries on demand.*

Research Methodology

This study combines primary inputs from industry experts across the Axial Spondyloarthritis (Axspa) value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Axial Spondyloarthritis (Axspa) industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Axial Spondyloarthritis (Axspa) Market Report

Global Axial Spondyloarthritis (Axspa) market size and growth projections (CAGR), 2024-2034

Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Axial Spondyloarthritis (Axspa) trade, costs, and supply chains

Axial Spondyloarthritis (Axspa) market size, share, and outlook across 5 regions and 27 countries, 2023-2034

Axial Spondyloarthritis (Axspa) market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034

Short- and long-term Axial Spondyloarthritis (Axspa) market trends, drivers, restraints, and opportunities

Porter’s Five Forces analysis, technological developments, and Axial Spondyloarthritis (Axspa) supply chain analysis

Axial Spondyloarthritis (Axspa) trade analysis, Axial Spondyloarthritis (Axspa) market price analysis, and Axial Spondyloarthritis (Axspa) supply/demand dynamics

Profiles of 5 leading companies—overview, key strategies, financials, and

products

Latest Axial Spondyloarthritis (Axspa) market news and developments

Additional Support

With the purchase of this report, you will receive

An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.

7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.

Complimentary report update to incorporate the latest available data and the impact of recent market developments.

** The updated report will be delivered within 3 working days*

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET SUMMARY, 2025

- 2.1 Axial Spondyloarthritis (Axspa) Industry Overview
 - 2.1.1 Global Axial Spondyloarthritis (Axspa) Market Revenues (In US\$ billion)
- 2.2 Axial Spondyloarthritis (Axspa) Market Scope
- 2.3 Research Methodology

3. AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET INSIGHTS, 2024-2034

- 3.1 Axial Spondyloarthritis (Axspa) Market Drivers
- 3.2 Axial Spondyloarthritis (Axspa) Market Restraints
- 3.3 Axial Spondyloarthritis (Axspa) Market Opportunities
- 3.4 Axial Spondyloarthritis (Axspa) Market Challenges
- 3.5 Tariff Impact on Global Axial Spondyloarthritis (Axspa) Supply Chain Patterns

4. AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET ANALYTICS

- 4.1 Axial Spondyloarthritis (Axspa) Market Size and Share, Key Products, 2025 Vs 2034
- 4.2 Axial Spondyloarthritis (Axspa) Market Size and Share, Dominant Applications, 2025 Vs 2034
- 4.3 Axial Spondyloarthritis (Axspa) Market Size and Share, Leading End Uses, 2025 Vs 2034
- 4.4 Axial Spondyloarthritis (Axspa) Market Size and Share, High Growth Countries, 2025 Vs 2034
- 4.5 Five Forces Analysis for Global Axial Spondyloarthritis (Axspa) Market
 - 4.5.1 Axial Spondyloarthritis (Axspa) Industry Attractiveness Index, 2025
 - 4.5.2 Axial Spondyloarthritis (Axspa) Supplier Intelligence
 - 4.5.3 Axial Spondyloarthritis (Axspa) Buyer Intelligence
 - 4.5.4 Axial Spondyloarthritis (Axspa) Competition Intelligence
 - 4.5.5 Axial Spondyloarthritis (Axspa) Product Alternatives and Substitutes Intelligence
 - 4.5.6 Axial Spondyloarthritis (Axspa) Market Entry Intelligence

5. GLOBAL AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET STATISTICS – INDUSTRY REVENUE, MARKET SHARE, GROWTH TRENDS AND FORECAST BY SEGMENTS, TO 2034

5.1 World Axial Spondyloarthritis (Axspa) Market Size, Potential and Growth Outlook, 2024- 2034 (\$ billion)

5.1 Global Axial Spondyloarthritis (Axspa) Sales Outlook and CAGR Growth By Types, 2024- 2034 (\$ billion)

5.2 Global Axial Spondyloarthritis (Axspa) Sales Outlook and CAGR Growth By Commercialized Therapies, 2024- 2034 (\$ billion)

5.3 Global Axial Spondyloarthritis (Axspa) Sales Outlook and CAGR Growth By Dosage Form, 2024- 2034 (\$ billion)

5.4 Global Axial Spondyloarthritis (Axspa) Sales Outlook and CAGR Growth By Treatment, 2024- 2034 (\$ billion)

5.5 Global Axial Spondyloarthritis (Axspa) Sales Outlook and CAGR Growth By End-Use, 2024- 2034 (\$ billion)

5.6 Global Axial Spondyloarthritis (Axspa) Market Sales Outlook and Growth by Region, 2024- 2034 (\$ billion)

6. ASIA PACIFIC AXIAL SPONDYLOARTHRITIS (AXSPA) INDUSTRY STATISTICS – MARKET SIZE, SHARE, COMPETITION AND OUTLOOK

6.1 Asia Pacific Axial Spondyloarthritis (Axspa) Market Insights, 2025

6.2 Asia Pacific Axial Spondyloarthritis (Axspa) Market Revenue Forecast By Types, 2024- 2034 (USD billion)

6.3 Asia Pacific Axial Spondyloarthritis (Axspa) Market Revenue Forecast By Commercialized Therapies, 2024- 2034 (USD billion)

6.4 Asia Pacific Axial Spondyloarthritis (Axspa) Market Revenue Forecast By Dosage Form, 2024- 2034 (USD billion)

6.5 Asia Pacific Axial Spondyloarthritis (Axspa) Market Revenue Forecast By Treatment, 2024- 2034 (USD billion)

6.6 Asia Pacific Axial Spondyloarthritis (Axspa) Market Revenue Forecast By End-Use, 2024- 2034 (USD billion)

6.7 Asia Pacific Axial Spondyloarthritis (Axspa) Market Revenue Forecast by Country, 2024- 2034 (USD billion)

6.7.1 China Axial Spondyloarthritis (Axspa) Market Size, Opportunities, Growth 2024-2034

6.7.2 India Axial Spondyloarthritis (Axspa) Market Size, Opportunities, Growth 2024-2034

6.7.3 Japan Axial Spondyloarthritis (Axspa) Market Size, Opportunities, Growth 2024-2034

6.7.4 Australia Axial Spondyloarthritis (Axspa) Market Size, Opportunities, Growth 2024- 2034

7. EUROPE AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET DATA, PENETRATION, AND BUSINESS PROSPECTS TO 2034

7.1 Europe Axial Spondyloarthritis (Axspa) Market Key Findings, 2025

7.2 Europe Axial Spondyloarthritis (Axspa) Market Size and Percentage Breakdown By Types, 2024- 2034 (USD billion)

7.3 Europe Axial Spondyloarthritis (Axspa) Market Size and Percentage Breakdown By Commercialized Therapies, 2024- 2034 (USD billion)

7.4 Europe Axial Spondyloarthritis (Axspa) Market Size and Percentage Breakdown By Dosage Form, 2024- 2034 (USD billion)

7.5 Europe Axial Spondyloarthritis (Axspa) Market Size and Percentage Breakdown By Treatment, 2024- 2034 (USD billion)

7.6 Europe Axial Spondyloarthritis (Axspa) Market Size and Percentage Breakdown By End-Use, 2024- 2034 (USD billion)

7.7 Europe Axial Spondyloarthritis (Axspa) Market Size and Percentage Breakdown by Country, 2024- 2034 (USD billion)

7.7.1 Germany Axial Spondyloarthritis (Axspa) Market Size, Trends, Growth Outlook to 2034

7.7.2 United Kingdom Axial Spondyloarthritis (Axspa) Market Size, Trends, Growth Outlook to 2034

7.7.2 France Axial Spondyloarthritis (Axspa) Market Size, Trends, Growth Outlook to 2034

7.7.2 Italy Axial Spondyloarthritis (Axspa) Market Size, Trends, Growth Outlook to 2034

7.7.2 Spain Axial Spondyloarthritis (Axspa) Market Size, Trends, Growth Outlook to 2034

8. NORTH AMERICA AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET SIZE, GROWTH TRENDS, AND FUTURE PROSPECTS TO 2034

8.1 North America Snapshot, 2025

8.2 North America Axial Spondyloarthritis (Axspa) Market Analysis and Outlook By Types, 2024- 2034 (\$ billion)

8.3 North America Axial Spondyloarthritis (Axspa) Market Analysis and Outlook By

Commercialized Therapies, 2024- 2034 (\$ billion)

8.4 North America Axial Spondyloarthritis (Axspa) Market Analysis and Outlook By Dosage Form, 2024- 2034 (\$ billion)

8.5 North America Axial Spondyloarthritis (Axspa) Market Analysis and Outlook By Treatment, 2024- 2034 (\$ billion)

8.6 North America Axial Spondyloarthritis (Axspa) Market Analysis and Outlook By End-Use, 2024- 2034 (\$ billion)

8.7 North America Axial Spondyloarthritis (Axspa) Market Analysis and Outlook by Country, 2024- 2034 (\$ billion)

8.7.1 United States Axial Spondyloarthritis (Axspa) Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.7.1 Canada Axial Spondyloarthritis (Axspa) Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.7.1 Mexico Axial Spondyloarthritis (Axspa) Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. SOUTH AND CENTRAL AMERICA AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET DRIVERS, CHALLENGES, AND FUTURE PROSPECTS

9.1 Latin America Axial Spondyloarthritis (Axspa) Market Data, 2025

9.2 Latin America Axial Spondyloarthritis (Axspa) Market Future By Types, 2024- 2034 (\$ billion)

9.3 Latin America Axial Spondyloarthritis (Axspa) Market Future By Commercialized Therapies, 2024- 2034 (\$ billion)

9.4 Latin America Axial Spondyloarthritis (Axspa) Market Future By Dosage Form, 2024- 2034 (\$ billion)

9.5 Latin America Axial Spondyloarthritis (Axspa) Market Future By Treatment, 2024- 2034 (\$ billion)

9.6 Latin America Axial Spondyloarthritis (Axspa) Market Future By End-Use, 2024- 2034 (\$ billion)

9.7 Latin America Axial Spondyloarthritis (Axspa) Market Future by Country, 2024- 2034 (\$ billion)

9.7.1 Brazil Axial Spondyloarthritis (Axspa) Market Size, Share and Opportunities to 2034

9.7.2 Argentina Axial Spondyloarthritis (Axspa) Market Size, Share and Opportunities to 2034

10. MIDDLE EAST AFRICA AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET OUTLOOK AND GROWTH PROSPECTS

- 10.1 Middle East Africa Overview, 2025
- 10.2 Middle East Africa Axial Spondyloarthritis (Axspa) Market Statistics By Types, 2024- 2034 (USD billion)
- 10.3 Middle East Africa Axial Spondyloarthritis (Axspa) Market Statistics By Commercialized Therapies, 2024- 2034 (USD billion)
- 10.4 Middle East Africa Axial Spondyloarthritis (Axspa) Market Statistics By Dosage Form, 2024- 2034 (USD billion)
- 10.5 Middle East Africa Axial Spondyloarthritis (Axspa) Market Statistics By Treatment, 2024- 2034 (USD billion)
- 10.6 Middle East Africa Axial Spondyloarthritis (Axspa) Market Statistics By End-Use, 2024- 2034 (USD billion)
- 10.7 Middle East Africa Axial Spondyloarthritis (Axspa) Market Statistics by Country, 2024- 2034 (USD billion)
 - 10.7.1 Middle East Axial Spondyloarthritis (Axspa) Market Value, Trends, Growth Forecasts to 2034
 - 10.7.2 Africa Axial Spondyloarthritis (Axspa) Market Value, Trends, Growth Forecasts to 2034

11. AXIAL SPONDYLOARTHRITIS (AXSPA) MARKET STRUCTURE AND COMPETITIVE LANDSCAPE

- 11.1 Key Companies in Axial Spondyloarthritis (Axspa) Industry
- 11.2 Axial Spondyloarthritis (Axspa) Business Overview
- 11.3 Axial Spondyloarthritis (Axspa) Product Portfolio Analysis
- 11.4 Financial Analysis
- 11.5 SWOT Analysis

12 APPENDIX

- 12.1 Global Axial Spondyloarthritis (Axspa) Market Volume (Tons)
- 12.1 Global Axial Spondyloarthritis (Axspa) Trade and Price Analysis
- 12.2 Axial Spondyloarthritis (Axspa) Parent Market and Other Relevant Analysis
- 12.3 Publisher Expertise
- 12.2 Axial Spondyloarthritis (Axspa) Industry Report Sources and Methodology

I would like to order

Product name: Axial Spondyloarthritis (Axspa) Market Outlook 2025-2034: Market Share, and Growth Analysis By Types (Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)), By Commercialized Therapies (Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)), By Dosage Form, By Treatment, By End-Use

Product link: <https://marketpublishers.com/r/A6100A158DC6EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A6100A158DC6EN.html>